An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus

Vaccine

Volumn 29, Issue 12, 2011, Pages 2308-2312

  Hatta, Yasuko ^a,b   Hatta, Masato ^a   Bilsel, Pamuk ^b   Neumann, Gabriele ^a   Kawaoka, Yoshihiro ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Flugen Inc   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Influenza vaccine; Live attenuated vaccine; M2 deletion; Pandemic (H1N1) 2009

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNITY; INFECTION CONTROL; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; DOGS; FEMALE; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED; VIRAL MATRIX PROTEINS; VIRULENCE; VIRUS CULTIVATION;

EID: 79951812356     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.023     Document Type: Article

References (19)

1. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25 (June)):2605-2615.
2. CDC Online Newsroom, Press Briefing Transcripts, Weekly 2009 H1N1 Flu Media Briefing, September 18, 2009, 12:00 p.m. [accessed 18.10.10]. http://www.cdc.gov/media/transcripts/2009/t090918.htm.
3. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363(21 (November)):2036-2044.
4. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69(3 (May)):517-528.
5. Helenius A. Unpacking the incoming influenza virus. Cell 1992, 69(4 (May)):577-578.
6. McCown M.F., Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006, 80(16 (August)):8178-8189.
7. McCown M.F., Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005, 79(6 (March)):3595-3605.
8. Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., et al. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 2006, 80(11 (June)):5233-5240.
9. Watanabe T., Watanabe S., Kim J.H., Hatta M., Kawaoka Y. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 2008, 82(5 (March)):2486-2492.
10. Watanabe S., Watanabe T., Kawaoka Y. Influenza A virus lacking M2 protein as a live attenuated vaccine. J Virol 2009, 83(11 (June)):5947-5950.
11. Hoffmann E., Stech J., Guan Y., Webster R.G., Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001, 6(12 (December)):2275-2289.
12. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999, 96(16 (August)):9345-9350.
13. Yamada S., Hatta M., Staker B.L., Watanabe S., Imai M., Shinya K., et al. Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog 2010, 6(8).
14. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460(7258 (August)):1021-1025.
15. Gojovic M.Z., Sander B., Fisman D., Krahn M.D., Bauch C.T. Modelling mitigation strategies for pandemic (H1N1) 2009. Can Med Assoc J 2009, 181(10 (November)):673-680.
16. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361(13 (September)):1260-1267.
17. Wareing M.D., Watson J.M., Brooks M.J., Tannock G.A. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57 A/Leningrad/134/47/57 and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol 2001, 65(1 (September)):171-177.
18. Tannock G.A., Paul J.A., Barry R.D. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 1984, 43(2 (February)):457-462.
19. Wacheck V., Egorov A., Groiss F., Pfeiffer A., Fuereder T., Hoeflmayer D., et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010, 201(3 (February)):354-362.